Representational oligonucleotide microarray analysis: Difference between revisions

Revision as of 09:56, 19 February 2009

Latest revision as of 11:34, 10 October 2024

(19 intermediate revisions by 15 users not shown)

Line 1:

{{redirect|ROMA||Roma (disambiguation)}}

{{Expert|date=February 2009}}

{{more citations needed|date=March 2018}}[[ImageFile:ROMARepresentational oligonucleotide microarray analysis (diagram).jpg|right|270px|thumb|ROMA.]]

'''Representational Oligonucleotideoligonucleotide Microarraymicroarray Analysisanalysis''' ('''ROMA''') is a technique that was developed by [[Michael Wigler]] and Rob Lucito at the [[Cold Spring Harbor Laboratory]] (CSHL) in 2003.{{FactCitation needed|date=July 2008}} Wigler and Lucito currently run laboratories at CSHL using ROMA to explore genomic copy number variation in cancer and other genetic diseases.

In this technique, two [[genome]]s are compared for their differences in copy number on a microarray. The ROMA technology emerged from a previous method called [[Representationalrepresentational Differencedifference Analysisanalysis]] (RDA). ROMA, in comparison to other [[comparative genomic hybridization]] (CGH) techniques, has the advantage of reducing the complexity of a genome with a restriction enzyme which highly increases the efficiency of genomic fragment hybridization to a microarray.

In ROMA, a genome is digested with a restriction enzyme, ligated with adapters specific to the restriction fragment sticky ends and amplified by PCR. After the PCR step, representations of the entire genome (restriction fragments) are amplified to pronounce relative increases, decreases or preserve equal copy number in the two genomes. The representations of the two different genomes are labeled with different fluorophores and co-hybridized to a microarray with probes specific to locations across the entire human genome. After analysis of the ROMA microarray image is completed, a copy number profile of the entire human genome is generated. This allows researchers to detect with high accuracy amplifications (amplicons) and deletions that occur across the entire genome.

In cancer, the genome becomes very unstable, resulting in specific regions that may be deleted (if they contain a tumor suppressor) or amplified (if they contain an [[oncogene]]). Amplifications and deletions have also been observed in the normal human population and are referred to as Copy Number Polymorphisms (CNPs). Jonathan Sebat was one of the first researchers to report in the journal 'Science' in 20032004 that these CNPs give rise to human genomic variation and may contribute to our phenotypic differences.<ref>Sebat, J. ''et al''. (2004) Large-scale copy number polymorphism in the human genome. Science '''305:''' 525–528</ref>{{FactCitation needed|date=July 2008}} Tremendous research efforts are being conducted now to understand the role of CNPs in normal human variation and neurological diseases such as autism. By understanding which regions of the genome have undergone copy number polymorphisms in disease, scientists can ultimately identify genes that are overexpressed or deleted and design drugs to compensate for these genes to cure genetic diseases.

==References==

{{reflist}}

* Lucito, R. ''et al.'' (2003) Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. ''Genome Res.'' '''13''', 2291-23052291–2305

[[Category:GenomicsMicroarrays]]

==External links==

* [http://www.nslij-genetics.org/cnv/ A bibliography on copy number variation]

[[Category:Genomics]]